Prothena reported $0 in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 12.78M 11.98M Sep/2026
ALKERMES USD 1.47B 5.38M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Amgen USD 51.61B 250M Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Immunic USD 0 0 Jun/2024
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
MacroGenics USD 163.16M 94.44M Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026